S&P 500   4,571.43 (+0.36%)
DOW   35,496.13 (+0.22%)
QQQ   391.57 (+0.35%)
AAPL   190.74 (+0.18%)
MSFT   378.98 (-0.97%)
META   332.43 (-1.94%)
GOOGL   136.00 (-0.87%)
AMZN   146.55 (-0.33%)
TSLA   249.74 (+1.22%)
NVDA   482.61 (+0.92%)
NIO   7.32 (+1.53%)
BABA   75.27 (-1.92%)
AMD   125.25 (+2.66%)
T   16.22 (+0.25%)
F   10.80 (+4.15%)
MU   78.11 (+2.61%)
CGC   0.55 (+2.07%)
GE   118.95 (+0.08%)
DIS   91.53 (-1.05%)
AMC   7.10 (+5.97%)
PFE   30.18 (+1.65%)
PYPL   58.78 (+0.53%)
XOM   103.33 (-0.55%)
S&P 500   4,571.43 (+0.36%)
DOW   35,496.13 (+0.22%)
QQQ   391.57 (+0.35%)
AAPL   190.74 (+0.18%)
MSFT   378.98 (-0.97%)
META   332.43 (-1.94%)
GOOGL   136.00 (-0.87%)
AMZN   146.55 (-0.33%)
TSLA   249.74 (+1.22%)
NVDA   482.61 (+0.92%)
NIO   7.32 (+1.53%)
BABA   75.27 (-1.92%)
AMD   125.25 (+2.66%)
T   16.22 (+0.25%)
F   10.80 (+4.15%)
MU   78.11 (+2.61%)
CGC   0.55 (+2.07%)
GE   118.95 (+0.08%)
DIS   91.53 (-1.05%)
AMC   7.10 (+5.97%)
PFE   30.18 (+1.65%)
PYPL   58.78 (+0.53%)
XOM   103.33 (-0.55%)
S&P 500   4,571.43 (+0.36%)
DOW   35,496.13 (+0.22%)
QQQ   391.57 (+0.35%)
AAPL   190.74 (+0.18%)
MSFT   378.98 (-0.97%)
META   332.43 (-1.94%)
GOOGL   136.00 (-0.87%)
AMZN   146.55 (-0.33%)
TSLA   249.74 (+1.22%)
NVDA   482.61 (+0.92%)
NIO   7.32 (+1.53%)
BABA   75.27 (-1.92%)
AMD   125.25 (+2.66%)
T   16.22 (+0.25%)
F   10.80 (+4.15%)
MU   78.11 (+2.61%)
CGC   0.55 (+2.07%)
GE   118.95 (+0.08%)
DIS   91.53 (-1.05%)
AMC   7.10 (+5.97%)
PFE   30.18 (+1.65%)
PYPL   58.78 (+0.53%)
XOM   103.33 (-0.55%)
S&P 500   4,571.43 (+0.36%)
DOW   35,496.13 (+0.22%)
QQQ   391.57 (+0.35%)
AAPL   190.74 (+0.18%)
MSFT   378.98 (-0.97%)
META   332.43 (-1.94%)
GOOGL   136.00 (-0.87%)
AMZN   146.55 (-0.33%)
TSLA   249.74 (+1.22%)
NVDA   482.61 (+0.92%)
NIO   7.32 (+1.53%)
BABA   75.27 (-1.92%)
AMD   125.25 (+2.66%)
T   16.22 (+0.25%)
F   10.80 (+4.15%)
MU   78.11 (+2.61%)
CGC   0.55 (+2.07%)
GE   118.95 (+0.08%)
DIS   91.53 (-1.05%)
AMC   7.10 (+5.97%)
PFE   30.18 (+1.65%)
PYPL   58.78 (+0.53%)
XOM   103.33 (-0.55%)

bluebird bio (BLUE) Competitors

$3.97
+0.13 (+3.39%)
(As of 10:40 AM ET)
Compare
Today's Range
$3.84
$4.05
50-Day Range
$2.61
$3.89
52-Week Range
$2.52
$8.58
Volume
878,637 shs
Average Volume
4.10 million shs
Market Capitalization
$434.08 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.62

BLUE vs. ALEC, PROK, ADAP, FUSN, CRBU, ALLO, AURA, VYGR, FDMT, and AGEN

Should you be buying bluebird bio stock or one of its competitors? The main competitors of bluebird bio include Alector (ALEC), ProKidney (PROK), Adaptimmune Therapeutics (ADAP), Fusion Pharmaceuticals (FUSN), Caribou Biosciences (CRBU), Allogene Therapeutics (ALLO), Aura Biosciences (AURA), Voyager Therapeutics (VYGR), 4D Molecular Therapeutics (FDMT), and Agenus (AGEN). These companies are all part of the "biological products, except diagnostic" industry.

bluebird bio vs.

Alector (NASDAQ:ALEC) and bluebird bio (NASDAQ:BLUE) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, community ranking, institutional ownership, media sentiment, dividends, valuation and profitability.

In the previous week, bluebird bio had 1 more articles in the media than Alector. MarketBeat recorded 3 mentions for bluebird bio and 2 mentions for Alector. bluebird bio's average media sentiment score of 1.43 beat Alector's score of 0.36 indicating that Alector is being referred to more favorably in the media.

Company Overall Sentiment
Alector Positive
bluebird bio Neutral

Alector presently has a consensus target price of $13.70, suggesting a potential upside of 152.77%. bluebird bio has a consensus target price of $7.62, suggesting a potential upside of 91.00%. Given bluebird bio's stronger consensus rating and higher probable upside, equities analysts plainly believe Alector is more favorable than bluebird bio.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Alector
1 Sell rating(s)
3 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.44
bluebird bio
1 Sell rating(s)
5 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.42

Alector has a net margin of -146.80% compared to Alector's net margin of -419.64%. Alector's return on equity of -34.32% beat bluebird bio's return on equity.

Company Net Margins Return on Equity Return on Assets
Alector-146.80% -74.78% -19.39%
bluebird bio -419.64%-34.32%-14.44%

bluebird bio received 891 more outperform votes than Alector when rated by MarketBeat users. Likewise, 72.27% of users gave bluebird bio an outperform vote while only 59.75% of users gave Alector an outperform vote.

CompanyUnderperformOutperform
AlectorOutperform Votes
141
59.75%
Underperform Votes
95
40.25%
bluebird bioOutperform Votes
1032
72.27%
Underperform Votes
396
27.73%

69.7% of Alector shares are owned by institutional investors. Comparatively, 87.4% of bluebird bio shares are owned by institutional investors. 14.0% of Alector shares are owned by company insiders. Comparatively, 2.1% of bluebird bio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Alector has a beta of 0.69, indicating that its share price is 31% less volatile than the S&P 500. Comparatively, bluebird bio has a beta of 0.87, indicating that its share price is 13% less volatile than the S&P 500.

Alector has higher revenue and earnings than bluebird bio. bluebird bio is trading at a lower price-to-earnings ratio than Alector, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alector$133.62M3.48-$133.31M-$1.69-3.27
bluebird bio$3.60M120.58-$266.58M-$0.74-5.36

Summary

bluebird bio beats Alector on 10 of the 18 factors compared between the two stocks.


Get bluebird bio News Delivered to You Automatically

Sign up to receive the latest news and ratings for BLUE and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BLUE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BLUE vs. The Competition

Metricbluebird bioBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$434.08M$2.57B$4.38B$6.75B
Dividend YieldN/A2.38%2.96%6.97%
P/E Ratio-5.363.4292.2910.61
Price / Sales120.58202.612,513.4858.15
Price / CashN/A23.6383.60140.83
Price / Book1.953.024.834.81
Net Income-$266.58M$55.18M$122.24M$175.97M
7 Day Performance4.75%2.07%2.01%2.07%
1 Month Performance45.69%14.55%14.50%10.52%
1 Year Performance-48.10%5.72%6.07%3.41%

bluebird bio Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ALEC
Alector
2.279 of 5 stars
$4.78
-2.8%
$13.70
+186.6%
-31.1%$402.17M$96.31M-2.83246Short Interest ↓
Positive News
PROK
ProKidney
1.7698 of 5 stars
$1.86
+5.7%
$15.50
+733.3%
-78.0%$437.34MN/A-3.1587Positive News
Gap Down
High Trading Volume
ADAP
Adaptimmune Therapeutics
1.7271 of 5 stars
$0.44
+2.3%
$4.65
+953.2%
-78.9%$438.95M$71.08M-0.90534Analyst Report
News Coverage
FUSN
Fusion Pharmaceuticals
2.4183 of 5 stars
$4.75
+6.5%
$11.17
+135.1%
+125.7%$343.93M$2.21M-2.91101Short Interest ↓
Positive News
High Trading Volume
CRBU
Caribou Biosciences
1.9943 of 5 stars
$5.30
-4.7%
$23.57
+344.7%
-31.7%$468.68M$34.61M-3.53137Short Interest ↓
ALLO
Allogene Therapeutics
2.1414 of 5 stars
$2.82
-5.7%
$15.35
+444.2%
-74.9%$474.54M$186,000.00-1.26359Gap Down
AURA
Aura Biosciences
1.8886 of 5 stars
$7.99
-3.9%
$21.00
+162.8%
-40.9%$305.70MN/A-4.1270
VYGR
Voyager Therapeutics
2.3332 of 5 stars
$6.71
-1.9%
$17.00
+153.4%
+23.9%$295.21M$158.40M5.46125
FDMT
4D Molecular Therapeutics
1.5158 of 5 stars
$11.95
-3.6%
$30.50
+155.2%
-48.2%$510.91M$21.99M-4.38140Short Interest ↑
AGEN
Agenus
2.2444 of 5 stars
$0.68
-8.1%
$8.10
+1,089.4%
-73.7%$283.15M$100.90M-0.83533Gap Up

Related Companies and Tools

This page (NASDAQ:BLUE) was last updated on 11/29/2023 by MarketBeat.com Staff

My Account -